Effect of Universal Testing and Treatment on HIV Incidence - HPTN 071 (PopART)
Richard J Hayes, Deborah Donnell, Sian Floyd, Nomtha Mandla, Justin Bwalya, Kalpana Sabapathy, Blia Yang, Mwelwa Phiri, Ab Schaap, Susan H Eshleman, Estelle Piwowar-Manning, Barry Kosloff, Anelet James, Timothy Skalland, Ethan Wilson, Lynda Emel, David Macleod, Rory Dunbar, Musonda Simwinga, Nozizwe Makola, Virginia Bond, Graeme Hoddinott, Ayana Moore, Sam Griffith, Nirupama Deshmane Sista, Sten H Vermund, Wafaa El-Sadr, David N Burns, James R Hargreaves, Katharina Hauck, Christophe Fraser, Kwame Shanaube, Peter Bock, Nulda Beyers, Helen Ayles, Sarah Fidler, HPTN 071 (PopART) Study Team, Richard J Hayes, Deborah Donnell, Sian Floyd, Nomtha Mandla, Justin Bwalya, Kalpana Sabapathy, Blia Yang, Mwelwa Phiri, Ab Schaap, Susan H Eshleman, Estelle Piwowar-Manning, Barry Kosloff, Anelet James, Timothy Skalland, Ethan Wilson, Lynda Emel, David Macleod, Rory Dunbar, Musonda Simwinga, Nozizwe Makola, Virginia Bond, Graeme Hoddinott, Ayana Moore, Sam Griffith, Nirupama Deshmane Sista, Sten H Vermund, Wafaa El-Sadr, David N Burns, James R Hargreaves, Katharina Hauck, Christophe Fraser, Kwame Shanaube, Peter Bock, Nulda Beyers, Helen Ayles, Sarah Fidler, HPTN 071 (PopART) Study Team
Abstract
Background: A universal testing and treatment strategy is a potential approach to reduce the incidence of human immunodeficiency virus (HIV) infection, yet previous trial results are inconsistent.
Methods: In the HPTN 071 (PopART) community-randomized trial conducted from 2013 through 2018, we randomly assigned 21 communities in Zambia and South Africa (total population, approximately 1 million) to group A (combination prevention intervention with universal antiretroviral therapy [ART]), group B (the prevention intervention with ART provided according to local guidelines [universal since 2016]), or group C (standard care). The prevention intervention included home-based HIV testing delivered by community workers, who also supported linkage to HIV care and ART adherence. The primary outcome, HIV incidence between months 12 and 36, was measured in a population cohort of approximately 2000 randomly sampled adults (18 to 44 years of age) per community. Viral suppression (<400 copies of HIV RNA per milliliter) was assessed in all HIV-positive participants at 24 months.
Results: The population cohort included 48,301 participants. Baseline HIV prevalence was 21% or 22% in each group. Between months 12 and 36, a total of 553 new HIV infections were observed during 39,702 person-years (1.4 per 100 person-years; women, 1.7; men, 0.8). The adjusted rate ratio for group A as compared with group C was 0.93 (95% confidence interval [CI], 0.74 to 1.18; P = 0.51) and for group B as compared with group C was 0.70 (95% CI, 0.55 to 0.88; P = 0.006). The percentage of HIV-positive participants with viral suppression at 24 months was 71.9% in group A, 67.5% in group B, and 60.2% in group C. The estimated percentage of HIV-positive adults in the community who were receiving ART at 36 months was 81% in group A and 80% in group B.
Conclusions: A combination prevention intervention with ART provided according to local guidelines resulted in a 30% lower incidence of HIV infection than standard care. The lack of effect with universal ART was unanticipated and not consistent with the data on viral suppression. In this trial setting, universal testing and treatment reduced the population-level incidence of HIV infection. (Funded by the National Institute of Allergy and Infectious Diseases and others; HPTN 071 [PopArt] ClinicalTrials.gov number, NCT01900977.).
Copyright © 2019 Massachusetts Medical Society.
Figures
References
- UNAIDS Fact Sheet World AIDS Day. Accesssed 21st January 2019 2018.
- UNAIDS Miles to go—closing gaps, breaking barriers, righting injustices. 2018;Accessed 21st January 2019.
- Granich R, Crowley S, Vitoria M, et al. . Highly active antiretroviral treatment as prevention of HIV transmission: review of scientific evidence and update. Current opinion in HIV and AIDS 2010;5:298-304.
- Chang LW, Serwadda D, Quinn TC, Wawer MJ, Gray RH, Reynolds SJ. Combination implementation for HIV prevention: moving from clinical trial evidence to population-level effects. The Lancet infectious diseases 2013;13:65-76.
- Cohen MS, Chen YQ, McCauley M, et al. . Antiretroviral Therapy for the Prevention of HIV-1 Transmission. The New England journal of medicine 2016;375:830-9.
- Cohen MS, Chen YQ, McCauley M, et al. . Prevention of HIV-1 infection with early antiretroviral therapy. The New England journal of medicine 2011;365:493-505.
- Rodger AJ, Cambiano V, Bruun T, et al. . Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy. JAMA 2016;316:171-81.
- Rodger AJ, Cambiano V, Bruun T, et al. . Risk of HIV transmission through condomless sex in MSM couples with suppressive ART: The PARTNER2 Study extended results in gay men. 22nd International AIDS conference, Amsterdam 2018;Abstract no WEAX0104LB:Accessed 21st January 2019.
- Eaton JW, Johnson LF, Salomon JA, et al. . HIV treatment as prevention: systematic comparison of mathematical models of the potential impact of antiretroviral therapy on HIV incidence in South Africa. PLoS Med 2012;9:e1001245.
- Granich R, Crowley S, Vitoria M, et al. . Highly active antiretroviral treatment for the prevention of HIV transmission. Journal of the International AIDS Society 2010;13:1.
- Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 2009;373:48-57.
- TEMPRANO ANRS Study Group A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa. The New England journal of medicine 2015;373:808-22.
- INSIGHT START Study Group Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. The New England journal of medicine 2015;373:795-807.
- World Health Organization Guideline on when to start Antiretroviral therapy and on Pre-exposure Prophylaxis for HIV. 2015;Accessed on 26th February 2016.
- UNAIDS 90-90-90: An ambitious treatment target to help end the AIDS epidemic. 2014;Accessed on 11th January 2016.
- Iwuji CC, Orne-Gliemann J, Larmarange J, et al. . Universal test and treat and the HIV epidemic in rural South Africa: a phase 4, open-label, community cluster randomised trial. Lancet HIV 2018;5:e116-e25.
- Havlir D, Charlebois E, Balzer L, et al. . SEARCH community cluster randomized study of HIV “test and treat” using multi-disease approach and streamlined care in rural Uganda and Kenya. 22nd International AIDS conference, Amsterdam 2018;Abstract no WEAX0106LB:Accessed 21st January 2019.
- Makhema MJ, Wirth K, Pretorius Holme M, et al. . Impact of prevention and treatment interventions on population HIV incidence: Primary results of the community-randomized Ya Tsie Botswana prevention project. 22nd International AIDS conference, Amsterdam 2018;Abstract no WEAX0105LB Accessed on 21st January 2019
- Hayes R, Ayles H, Beyers N, et al. . HPTN 071 (PopART): rationale and design of a cluster-randomised trial of the population impact of an HIV combination prevention intervention including universal testing and treatment - a study protocol for a cluster randomised trial. Trials 2014;15:57.
- Cori A, Ayles H, Beyers N, et al. . HPTN 071 (PopART): a cluster-randomized trial of the population impact of an HIV combination prevention intervention including universal testing and treatment: mathematical model. PloS one 2014;9:e84511.
- Donnell D, Floyd S, Hayes R, HPTN 071 Protocol Team HPTN 071 (PopART) Study Statistical Analysis Plan. 2018;Accessed 27th January 2019.
- Eldridge S, Kerry S. A Practical Guide to Cluster Randomised Trials in Health Services Research. DOI:10.1002/9781119966241 2012;Copyright © 2012 John Wiley & Sons, Ltd.
- Hayes R, Moulton L. Cluster Randomised Trials. doiorg/104324/9781315370286 2017;New York: Chapman and Hall/CRC.
- Tanser F, Barnighausen T, Grapsa E, Zaidi J, Newell ML. High coverage of ART associated with decline in risk of HIV acquisition in rural KwaZulu-Natal, South Africa. Science 2013;339:966-71.
- Tanser F, Vandormael A, Cuadros D, et al. . Effect of population viral load on prospective HIV incidence in a hyperendemic rural African community. Sci Transl Med 2017;9.
- Justman JE, Mugurungi O, El-Sadr WM. HIV Population Surveys - Bringing Precision to the Global Response. The New England journal of medicine 2018;378:1859-61.
- Eisinger RW, Dieffenbach CW, Fauci AS. HIV Viral Load and Transmissibility of HIV Infection: Undetectable Equals Untransmittable. JAMA : the journal of the American Medical Association 2019.
- Fayorsey RN, Wang C, Chege D, et al. . Effectiveness of a Lay Counselor-Led Combination Intervention for Retention of Mothers and Infants in HIV Care: A Randomized Trial in Kenya. J Acquir Immune Defic Syndr 2019;80:56-63.
- Hargreaves JR, Delany-Moretlwe S, Hallett TB, et al. . The HIV prevention cascade: integrating theories of epidemiological, behavioural, and social science into programme design and monitoring. Lancet HIV 2016;3:e318-22.
- Krishnaratne S, Hensen B, Cordes J, Enstone J, Hargreaves JR. Interventions to strengthen the HIV prevention cascade: a systematic review of reviews. Lancet HIV 2016;3:e307-17.
- Hayes R, Floyd S, Schaap A, et al. . A universal testing and treatment intervention to improve HIV control: One-year results from intervention communities in Zambia in the HPTN 071 (PopART) cluster-randomised trial. PLoS Med 2017;14:e1002292.
- Floyd S, Ayles H, Schaap A, et al. . Towards 90-90: Findings after two years of the HPTN 071 (PopART) cluster-randomized trial of a universal testing-and-treatment intervention in Zambia. PloS one 2018;13:e0197904.
- Stopard IJ, McGillen JB, Hauck K, Hallett TB. The influence of constraints on the efficient allocation of resources for HIV prevention: a modelling study. AIDS 2019.
Source: PubMed